The short version
Difficulty getting aroused or lubricated is common, has many possible causes, and several of them are medical. A GP is the right first stop, especially if the change is recent, followed a new medication, childbirth, surgery or menopause, or comes with pain, bleeding or unusual discharge. Sudden severe pelvic pain or heavy bleeding is urgent: call 000 (Australia), 999 (UK) or 911 (US).
The approaches with the most support are not exotic: identifying medical or medication causes, psychological therapies including mindfulness-based programmes, sex-therapy exercises, moisturisers or lubricants, and, where a prescriber judges it suitable, hormonal treatment. Body-based and breath practices may suit some people as an adjunct, but trials of them for female arousal specifically were not identified in the sources used for this guide. Evidence strength is labelled in the text as STRONG, MODERATE, EMERGING, CONTESTED or UNEVIDENCED. This is educational information, not individual medical advice.
What is being described
The DSM-5 combines low desire and low arousal in women into one category, female sexual interest/arousal disorder (FSIAD). As reproduced in a 2023 study by Weiss and colleagues, the criteria require a lack of, or significantly reduced, sexual interest or arousal, shown by at least three of six features: absent or reduced interest in sexual activity; sexual or erotic thoughts or fantasies; initiation of sexual activity; excitement or pleasure during sexual activity; interest or arousal in response to sexual cues; and genital sensations during sexual activity. The problem must last at least six months, cause clinically significant distress, and not be better explained by another mental disorder or by substance or medication use.
The merged category is not universally accepted. A 2019 international consensus statement on testosterone therapy (Davis and colleagues) recommended that hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD) be categorised separately when treatment is considered, because they overlap but have distinct causes, risk factors and responses to treatment. In practice, "I do not feel like it" and "my body is not responding" can be different problems.
On desire, Rosemary Basson's influential model (2000) proposed that, particularly in established relationships, desire is often responsive: it emerges after sexual stimulation and arousal begin, rather than arriving first. In Basson's 2001 clinical report of 47 women referred for low desire, all could relate to the model, and identifying missing components of their sexual response cycle was itself reported as therapeutic. It is a descriptive model, not a rule for every woman; spontaneous desire is also common.
Genital and subjective arousal can diverge
Arousal has at least two layers: the body's physical response (blood flow and lubrication) and the felt sense of being turned on. In a meta-analysis of 132 laboratory studies (2,505 women and 1,918 men), Chivers and colleagues (2010) found the agreement between self-reported and genital arousal was far weaker in women (r = .26) than in men (r = .66). Stimulus variability and the timing of the self-report moderated the gap, so method matters.
This has two practical implications. First, a woman can feel little arousal while her body is responding physically, or the reverse. Genital response is not a measure of wanting or consenting to sex, and a lack of lubrication is not proof of disinterest. These are editorial readings, not findings of the studies. Second, Handy and Meston (2018) noted that laboratory studies have largely failed to find genital-response differences between women with and without FSAD. In their study of 26 women meeting FSAD criteria, the women could perceive their level of genital arousal, and greater interoception (body awareness) was linked with a closer match between perceived and physiological genital arousal, but not between subjective arousal and genital response. This is one small study, and it tempers the idea that body awareness automatically aligns the felt and physical layers.
Evidence that the gap can narrow is limited. In a pilot trial of 20 women with sexual distress and a history of childhood sexual abuse, Brotto, Seal and Rellini (2012) reported that two sessions of group mindfulness-based therapy raised subjective arousal relative to genital arousal more than a cognitive behavioural group did. Label: EMERGING (small sample, very brief intervention).
Medical contributors, and a GP-first assessment
Many medical factors can reduce arousal or lubrication, so assessment comes before any self-directed programme.
Menopause. The genitourinary syndrome of menopause (GSM) is described in a 2026 BMS consensus statement (Briggs) as a chronic and progressive condition linked to oestrogen deficiency, affecting vulval, vaginal, bladder and urethral tissue. It notes that symptoms may emerge years after menopause and that under-diagnosis is common.
Medications. In a meta-analysis, Serretti and Chiesa (2009) found antidepressants differed widely in treatment-emergent sexual dysfunction. Rates ranged from 25.8% to 80.3% of patients for drugs such as sertraline, venlafaxine, citalopram, paroxetine and fluoxetine, while bupropion, mirtazapine and agomelatine showed no significant difference from placebo; arousal difficulties were among the measured outcomes. Any change to an antidepressant is the prescriber's decision, and stopping suddenly can cause problems (general safety guidance, not from that study).
Hormonal contraception. Evidence is inconsistent: Saadedine and Faubion (2024) reported that associations with sexual dysfunction vary across studies and between methods. Pastor and colleagues (2013) reviewed 36 studies of combined pills and reported that about 85% of users noted an increase or no change in libido and 15% a decrease. That review addressed desire, not arousal specifically.
Thyroid and diabetes. Salari and colleagues (2024) pooled nine cross-sectional studies and estimated sexual dysfunction in 44.8% of women with thyroid disorders (95% CI 33.8 to 56.2), without a comparison group, so cause cannot be shown. Tandoğan (2026) found lower Female Sexual Function Index scores in women with diabetes than in controls, with very high heterogeneity and a call for cautious interpretation.
Surgery, cancer treatment and childbirth. A 2026 review by Sha and colleagues describes how gynaecological cancer treatment can bring early menopause, disrupt pelvic blood vessels and nerves, and alter pelvic anatomy. After birth, a 2025 systematic review by Boarta and colleagues found perineal injury and early pain consistently tracked with worse sexual outcomes, breastfeeding was often associated with lower early sexual function, and partner support and a more positive body image correlated with better scores.
Pain. Provoked vestibulodynia, pain at the entrance of the vagina on touch or attempted penetration, is described as the most common subtype of chronic vulvar pain (Morin and colleagues, 2021). Pain can produce avoidance and anticipation that suppress arousal (general clinical observation).
A GP assessment typically covers the timeline, medicines and contraception, menopausal status, pain, mood, sleep, alcohol and other substances, plus examination or tests where indicated. This is general practice rather than one source; the Davis consensus (2019) also stresses thorough clinical assessment for HSDD.
Psychological and relational contributors
Stress and distraction have the best direct evidence. Hamilton and Meston (2013) compared 15 women with high chronic stress with 15 with average stress while they watched an erotic film. The high-stress group had lower genital arousal but not lower psychological arousal, higher cortisol and more distraction, and distraction was the main predictor of lower genital arousal. The groups were small, but the finding fits the attentional account behind mindfulness-based treatment.
A 2026 systematic review of six observational studies (Marvi and colleagues) linked poorer body image with reduced sexual function in peri- and postmenopausal women; observational designs cannot establish direction.
Context and stimulation matter. In Basson's 2001 clinical series, sexual stimuli and context were minimal in 53% of 47 women referred for low desire, psychological factors reducing arousability were identified in 85%, and androgen deficiency contributed in 25%. Arousal generally needs adequate, wanted stimulation in a setting that feels safe and unhurried, which is a reason to look at what happens during sex, not only at the woman's body. Whether a partner's touch matches what she finds arousing is a plausible but under-studied factor (general observation).
In a 2019 study of 97 women diagnosed with FSIAD and their partners, Hogue and colleagues linked motivation to meet a partner's sexual needs with better sexual well-being, but not when it meant neglecting one's own needs, where partners reported more distress. In Brotto and Basson's 2014 trial, rising mindfulness and falling depressive symptoms predicted improved desire.
Treatments, by strength of evidence
Psychological therapies. Frühauf and colleagues (2013) pooled 20 randomised trials of psychological interventions for sexual dysfunction against waiting lists and found a moderate overall effect on symptom severity (d = 0.58), with good evidence for female HSDD and orgasmic disorder and less for other conditions. Label: MODERATE for desire and orgasm difficulties; EMERGING for arousal difficulty specifically, since no arousal-specific pooled evidence was identified.
Mindfulness-based programmes. Brotto and Basson (2014) randomised 117 women with low desire and arousal to four 90-minute group sessions (mindfulness meditation, cognitive therapy and education) or delayed treatment. Compared with the waiting list, treatment improved desire, arousal, lubrication, satisfaction and overall sexual function; 95 women completed the 6-month follow-up. Distress fell in both groups. A 2025 meta-analysis of 11 studies (Çuvadar and Özcan) found improved sexual function (SMD 0.461) and reduced sexual distress, with high heterogeneity (I-squared 79%). Label: MODERATE, with caveats: waiting-list controls, short follow-up, variable study quality.
Sex therapy and sensate focus. Sensate focus is a structured sequence of non-demand touch exercises, originating with Masters and Johnson, that shifts attention from performance to sensation. A 2019 review by Avery-Clark, Weiner and Adams-Clark concluded it continues to be an effective sex-therapy technique, though its abstract does not describe study designs, and the authors are teachers of the method. No controlled trial specific to female arousal was identified in the sources used here. Label: EMERGING for arousal; widely used in clinical practice.
Moisturisers, lubricants and local oestrogen. For GSM symptoms, a Cochrane review by Lethaby and colleagues (2016) pooled 30 trials (6,235 women) and judged the evidence low to moderate quality, with low-quality evidence that vaginal oestrogen improves vaginal atrophy symptoms compared with placebo. Yet in a 12-week trial of 302 postmenopausal women (Mitchell and colleagues, 2018), neither a vaginal oestradiol tablet nor a moisturiser reduced the most bothersome symptom more than placebo, as all groups improved. Label: CONTESTED on how much is gained beyond placebo; whether to use local oestrogen, and which product, is the prescriber's decision. In a 150-woman trial (Khosravi and colleagues, 2022), lubricant gel and Kegel exercise each improved sexual function in menopausal women versus no intervention. Label: EMERGING.
Medicines for desire. In a meta-analysis of 36 randomised trials (8,480 participants), Islam and colleagues (2019) found testosterone improved desire (SMD 0.36) and arousal (SMD 0.28) in postmenopausal women, with more acne and hair growth and no serious adverse events recorded, while the 2019 consensus statement limited its recommendation to postmenopausal women with HSDD and said it cannot be generalised to other subtypes. Flibanserin, in a 2016 meta-analysis of randomised trials involving 5,914 women (Jaspers and colleagues), added about half a satisfying sexual event per month with more dizziness, somnolence and nausea, and the evidence was graded very low quality. Label: MODERATE for testosterone in postmenopausal HSDD; weak for flibanserin. Neither is established for isolated arousal difficulty. Both are specialist prescribing decisions.
Pelvic-floor physiotherapy for pain. Where pain drives the problem, this has the strongest direct evidence. Morin and colleagues (2021) randomised 212 women with provoked vestibulodynia to multimodal physical therapy or topical lidocaine; physical therapy reduced intercourse pain more, with the gap maintained at 6 months, and 79% reported being much or very much improved against 39% with lidocaine. Label: MODERATE for pain and associated sexual function; it addresses pain, not arousal directly.
Where body-based, breath and somatic practices fit
The defensible case is at the level of mechanism, not tradition. Attention is one mechanism: mindfulness and body-scan practice train attention toward bodily sensation and away from self-monitoring, which Hamilton and Meston's distraction finding supports as plausible. Autonomic state is another. Lorenz and colleagues (2012) found, in 52 sexually functional women, that moderate sympathetic nervous system activation was associated with higher genital arousal, and very low or very high activation with lower arousal. It does not follow that breathing techniques raise arousal; no trial linking breath practice to arousal in women was identified. Label: EMERGING as a mechanism, UNEVIDENCED as a treatment.
Exercise has also been tested. Lorenz and Meston (2012) found in 47 women with antidepressant-related arousal problems that 20 minutes of exercise before an erotic film increased laboratory genital arousal, and a 2014 crossover trial of 52 women found it improved desire. Label: EMERGING.
A randomised trial of Somatic Experiencing for post-traumatic stress disorder (Brom and colleagues, 2017; 63 participants) was identified, but none for sexual function. Whether body-based trauma work improves arousal difficulty is UNEVIDENCED, as is tantric or neo-tantric practice. A reasonable view is that they are an optional adjunct, particularly where numbness, dissociation or distraction predominates, alongside rather than instead of medical care and evidence-based therapy.
What is not supported
No identified evidence supports claims that one technique or breath pattern cures arousal disorder, that a lack of lubrication always means a psychological problem, or that genital response reliably reflects desire. Supplements are weakly supported: in a 2021 systematic review of L-arginine products (Cieri-Hutcherson and colleagues; the review concerned desire-related conditions rather than arousal specifically), 4 of 7 studies had potential risk-of-bias concerns. Mindfulness or breathing has not been shown to reverse medication effects.
Who to see, and pacing with a trauma history
A GP is the first step for new or unexplained change, medication questions, menopause, postpartum concerns or pain. A pelvic-floor physiotherapist suits pain, tightness or difficulty with penetration. A sex therapist or psychologist trained in sexual health suits stress, distraction, relationship patterns, shame and body image.
If sex or touch has been associated with abuse, go slowly. In 137 women with post-traumatic stress disorder after childhood sexual abuse (Weiss and colleagues, 2023), most reported sexual problems but only 2.6% met FSIAD criteria, and PTSD severity predicted more FSIAD features. Body awareness exercises can bring up distress, so pacing should be guided by a trauma-informed clinician, with stabilisation first and freedom to stop at any time. If you are in danger or distress: Australia 000, Lifeline 13 11 14, 1800RESPECT 1800 737 732; UK 999, Samaritans 116 123; US 911, 988.